SCHEMBL20205979

SCHEMBL20205979

CN1CCC(COCC(=O)N(C)C)(Cc2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.47
NPFFR1 Q9GZQ6 1/20 0.43
NPFFR2 Q9Y5X5 1/20 0.43
OPRM1 P35372 4/20 0.41
SLC6A4 P31645 2/20 0.41
SLC22A1 O15245 1/20 0.41
ADRA1A P35348 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
KCNH2 Q12809 1/20 0.41
OPRL1 P41146 1/20 0.40
SCN1A P35498 1/20 0.39
SCN2A Q99250 1/20 0.39
SCN3A Q9NY46 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20147388 0.87 RET (0.46) RETOPRM1OPRD1OPRK1KCNH2
SCHEMBL20069534 0.80 RET (0.47) RETNPFFR1NPFFR2OPRM1SLC6A4
SCHEMBL20069393 0.78 NPFFR1 (0.40) NPFFR1NPFFR2OPRM1SLC6A4SLC22A1
SCHEMBL16838111 0.76 MEN1 (0.43) RETNPFFR1NPFFR2OPRM1SLC6A4
SCHEMBL31389328 0.75 MC4R (0.50) NPFFR1NPFFR2OPRM1OPRK1OPRL1
SCHEMBL16838122 0.72 MEN1 (0.58) MEN1KMT2ALMNARAB9AALDH1A1
SCHEMBL20069568 0.72 CYP11B2 (0.32) OPRM1SLC6A4SLC22A1ADRA1AOPRD1
SCHEMBL13855456 0.71 NPFFR1 (0.48) NPFFR1NPFFR2OPRM1SLC6A4SLC22A1
SCHEMBL20158623 0.71 RET (0.46) RETNPFFR1NPFFR2OPRM1OPRK1
SCHEMBL20069537 0.70 OPRM1 (0.45) RETNPFFR1NPFFR2OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885NPFFR1 2115/4885NPFFR2 2916/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885NPFFR1 2115/4885NPFFR2 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.